Meeting
2012 Genitourinary Cancers Symposium
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) as third- to fourth-line therapy for male germ cell tumors (GCT).
Authors
Andrea Necchi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Necchi , Nicola Nicolai , Patrizia Giannatempo , Daniele Raggi , Giuseppa Napoli , Mario Catanzaro , Davide Biasoni , Tullio Torelli , Angelo Milani , Silvia Stagni , Luigi Piva , Filippo G. De Braud , Alessandro M. Gianni , Roberto Salvioni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session D: Penile, Urethral, Urothelial, and Testicular Cancers
Track
Urothelial Carcinoma,Penile, Urethral, and Testicular Cancer
Sub Track
Penile, Urethral, and Testicular Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 341)
DOI
10.1200/jco.2012.30.5_suppl.341
Abstract #
341
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2023 ASCO Annual Meeting
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
First Author: Hailiang Zhang
Poster
2023 ASCO Genitourinary Cancers Symposium
Early efficacy results from atezolizumab (ATZ) with split doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA).
First Author: Guillermo de Velasco